A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemonaive patients with advanced non-small cell lung cancer
Vansteenkiste, Johan × Ramlau, Rodryg von Pawel, Joachim San Antonio, Belen Eschbach, Corinna Szczesna, Aleksandra Kennedy, Liam Visseren-Grul, Carla Chouaki, Nadia Reck, Martin #
Oncology: International Journal of Cancer Research and Treatment vol:82 issue:1 pages:25-9
Enzastaurin is a serine/threonine kinase inhibitor that targets protein kinase C and AKT pathways. Enzastaurin and pemetrexed demonstrated synergy in preclinical studies. This trial was designed to evaluate the safety and efficacy of first-line enzastaurin plus cisplatin-pemetrexed in advanced non-small cell lung cancer (NSCLC).